Lecture
MCBIM Colloquium: Lightning Up Platinum Complexes for Tumor-Targeted Anticancer Therapy
- Date
- Friday 24 May 2024
- Time
- Location
-
Gorlaeus Building
Einsteinweg 55
2333 CC Leiden - Room
- CM.3.23
Abstract
The Platinum(II) complexes cisplatin and its derivatives dominate the field of anticancer chemotherapeutic agents. Despite their clinical success, these compounds are associated with severe side effects (i.e., nerve and kidney damage, nausea, vomiting, bone marrow suppression).
To overcome these drawbacks, increasing research efforts are devoted towards Platinum(IV) complexes as prodrugs. These compounds are ideally inactive under physiological conditions, but are reduced into their analogous Platinum(II) therapeutically active compounds within the cancerous cells.
Typically, the reduction is caused by reducing agents such as glutathione, metallothionein, or ascorbic acid which are present in high levels within cancer cells.[1] However, as these agents are also available in healthy cells, this mechanism of action is associated with poor selectivity and low efficiency. To overcome this limitation, this presentation will focus on the tumor-targeted delivery and selective activation of Platinum(IV) prodrugs with light or ultrasound for anticancer therapy with high precision and selectivity.[2-3]
As an outlook, the presentation will further suggest how these metal complexes could be chemically modified to efficiently generate an immune response towards the treatment of multiple distant tumors or tumor metastases.
References
- J. Karges, ChemNanoMat 2023, 9, e202300295.
- D. Wei, Y. Huang, B. Wang, L. Ma, J. Karges, H. Xiao, Angew. Chem. Int. Ed. 2022, 61, e202201486
- G. Liang, T. Sadhukhan, S. Banerjee, D. Tang, H. Zhang, M. Cui, N. Montesdeoca, J. Karges, H. Xiao, Angew. Chem. Int. Ed. 2023, 62, e202301074.